Boston Scientific, headquartered in Marlborough, Mass, recently announced the European launch of the Precision Novi Spinal Cord Stimulator (SCS) System at the International Neuromodulation Society in Montreal, Canada.

A company news release reports that the 16-contact primary cell device holds a CE mark for the treatment of chronic pain, and is a small high-capacity primary cell device.

The Precision Novi implant’s shape is engineered to offer an optimized level of comfort to patients with pain treated using primary cell therapy. The device is powered by Illumina 3D Software, which is made to allow physicians to target pain precisely with point-and-click simplicity. The Precision Novi System also features a small high-capacity battery, allowing effective pain relief to be delivered from a much smaller device, the release says. The technology is also designed to couple with a wireless remoter, offering patients flexibility and control over pain management.

“We are excited to expand our range of therapeutic solutions for patients suffering from chronic pain. The Precision Novi System brings the power of our Illumina 3D Algorithm to the more than 60% of SCS patients in Europe who are treated with primary cell therapy,” says Maulik Nanavaty, president, Neuromodulation, Boston Scientific.

The Precision Novi intuitive Illumina 3D neural targeting software, the release says, is built to incorporate three-dimensional lead location, as well as the conductivity of the spinal cord and surrounding tissue. The point-and-click technology automatically calculates the optimal programming configuration to target the selected pain area.

The release states that the Precision Novi SCS System is not available in the US.

[Source: Boston Scientific]